In one paragraphArticle in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Julian Ramírez-BelloSubdirección de Investigación Clínica, Instituto Nacional de Cardiología Ignacio Chávez, México City 14080, Mexico.ORCID 0000-0002-4153-9315 Isaac Alberto López-BriceñoLaboratorio de Hematología, Centro de Investigaciones Regionales "Dr. Hideyo Noguchi", Universidad Autónoma de Yucatán, Mérida 97069, Mexico.ORCID 0000-0001-9334-4707 Guillermo Valencia-PachecoLaboratorio de Hematología, Centro de Investigaciones Regionales "Dr. Hideyo Noguchi", Universidad Autónoma de Yucatán, Mérida 97069, Mexico.ORCID 0000-0002-6633-130X Rosa Elda Barbosa-CobosServicio de Reumatología, Hospital Juárez de México, México City 07760, Mexico.ORCID 0000-0003-2191-7427 Gabriela Hernández-MolinaDepartamento de Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zurbirán, México City 14080, Mexico.ORCID 0000-0001-7958-0391 Silvia Jiménez-MoralesLaboratorio de Innovación y Medicina de Precisión, Núcleo "A", Instituto Nacional de Medicina Genómica, México City 14610, Mexico.ORCID 0000-0002-6590-9712 Iván Sammir Aranda-UribeLaboratorio de Biología Celular y Molecular, Departamento de Ciencias Farmacéuticas, División de Ciencias de la Salud, Universidad Autónoma de Quintana Roo, Chetumal 77019, Mexico.ORCID 0000-0003-1219-0975 Isela Montúfar-RoblesDivisión de Investigación, Hospital Juárez de México, México City 07760, Mexico.ORCID 0000-0002-1141-452X Swapan K NathArthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA.ORCID 0000-0001-6013-9328 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Primary Sjögren's syndrome (pSS) is an autoimmune disease characterized by inflammation and damage to salivary and lacrimal glands. Its etiology involves both genetic and environmental factors. Among susceptibility genes,
Indexed as
Genetic Predisposition to DiseaseInterferon Regulatory FactorsPolymorphism, Single NucleotideSjogren's SyndromeAdultCase-Control StudiesFemaleGene FrequencyHaplotypesHumansMaleMexicoMiddle AgedRisk FactorsInterferon Regulatory FactorsIRF5 protein, humangenetic variantsIRF5primary Sjögren’s syndromesusceptibility
Identifiers
PMID41596252
PMCPMC12841342
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390